Navigation Links
New Jersey Health Foundation Awards $50,000 Grant For Research to Facilitate Stem Cell Growth

NEW BRUNSWICK, N.J., Oct. 21, 2013 /PRNewswire-USNewswire/ -- Dr. Steven Levison has received a $50,000 Innovation Stage Funding Grant from New Jersey Health Foundation to advance research that could make stem cell growth easier and less expensive for researchers, scientists and others interested in using stem cells to advance medical studies.

Dr. Levison, a professor in the Department of Neurology and Neurosciences at Rutgers New Jersey Medical School (NJMS), has worked collaboratively with colleagues at NJMS and at the New Jersey Institute of Technology to develop a multifunctional matrix that allows neural stem cells to be propagated as undifferentiated cells without daily feeding.

"Our cell culture matrices and supplements can be used in regenerative medicine, biotechnology and life science research," explained Dr. Levison. "We can manufacture products that don't contain animal components so that they are suitable for clinical applications."

Dr. Levison explained that he and his research team have formulated and rigorously tested a novel growth matrix that promotes the proliferation and multipotency of neural stem cells. Commercially available matrices today, he said, do not incorporate defined growth factors.  While some matrices do contain growth factors, they are not defined or suitable for therapeutic use.

"We are very interested in helping Dr. Levison advance his research because we believe this product could be commercialized successfully to be of tremendous benefit to the research community," explained Dr. George F. Heinrich, vice chair and CEO of New Jersey Health Foundation.  "His unique product reduces the time-consuming and tedious task of feeding stem cells on a daily basis, which will save researchers time and money."

Dr. Levison and his research team are presently modifying the scaffold to incorporate a variety of growth factors known to be beneficial for propagating other types of stem cells and progenitors. 

Through the Innovation Stage Funding program, New Jersey health Foundation ( has allocated $500,000 to provide grants from $10,000 to $50,000 each to researchers at the Rutgers School of Biomedical and Health Sciences who have promising ideas to advance an intellectual property toward commercialization through a start-up. 

About New Jersey Health Foundation
New Jersey Health Foundation ( is a not-for-profit corporation that supports biomedical research and health-related education programs in New Jersey through its matching program, its Grants Program and its affiliate, Foundation Venture Capital Group ( which makes private equity investments in life science start- up companies in New Jersey headed toward commercialization.

SOURCE New Jersey Health Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunrise Pharmaceutical, Inc. Sued for Violation of New Jersey Consumer Fraud Act
2. Cardiac Science signs contract to provide Powerheart AEDs to the state of New Jersey
3. Big Pharma to Come Together at ChemOutsourcing 2013 in Long Branch, New Jersey, Sept 16-19
4. ChemOutsourcing Announces 100 CMO and CRO Exhibitors for September 2013 Show in Long Branch, New Jersey
5. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
6. NJBIZ Honors New Jerseys General Counsels
7. Growth Fuels Expansion As PendoTECH Relocates New Jersey Headquarters
8. South Jersey Healthcare Selects Perioperative Management By Surgical Information Systems
9. New Jersey Health Foundation Awards First Two Innovation Stage Funding Grants
10. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
11. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):